NAV

Linperlisib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Linperlisib
DrugBank Accession Number
DB17235
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 588.7
Monoisotopic: 588.253017652
Chemical Formula
C28H37FN6O5S
Synonyms
  • Methanesulfonamide, n-(5-(6-fluoro-8-((4-(1-hydroxy-1-methylethyl)-1-piperidinyl)methyl)-2-(4-morpholinyl)-4-quinazolinyl)-2-methoxy-3-pyridinyl)-
  • N-(5-(6-fluoro-8-((4-(2-hydroxypropan-2-yl) piperidin-1-yl)methyl)-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-)methanesulfonamide
  • N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl) piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-]methanesulfonamide
  • N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-yl]methanesulfonamide
  • Pi3k.delta.-in-2

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
05HYK3CV9N
CAS number
1702816-75-8
InChI Key
NVWKNQGHVMMAJW-UHFFFAOYSA-N
InChI
InChI=1S/C28H37FN6O5S/c1-28(2,36)20-5-7-34(8-6-20)17-19-13-21(29)15-22-24(31-27(32-25(19)22)35-9-11-40-12-10-35)18-14-23(33-41(4,37)38)26(39-3)30-16-18/h13-16,20,33,36H,5-12,17H2,1-4H3
IUPAC Name
N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-2-(morpholin-4-yl)quinazolin-4-yl)-2-methoxypyridin-3-yl]methanesulfonamide
SMILES
COC1=NC=C(C=C1NS(C)(=O)=O)C1=C2C=C(F)C=C(CN3CCC(CC3)C(C)(C)O)C2=NC(=N1)N1CCOCC1

References

General References
Not Available
ChemSpider
67886313
BindingDB
309960
ChEMBL
CHEMBL4574601

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentPeripheral T/NK Cell Lymphoma (R/R PTCL)1
1Not Yet RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentAutoimmune Hemolytic Anemia / Failure of Two Rounds of Treatment1
1RecruitingTreatmentRelapsed/Refractory Large Granular T Lymphocytic Leukemia1
1, 2RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL)1
1, 2RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)3
Not AvailableNot Yet RecruitingNot AvailableFocus on the Lymphoma Including B/T-cell Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0794 mg/mLALOGPS
logP2.94ALOGPS
logP1.38Chemaxon
logS-3.9ALOGPS
pKa (Strongest Acidic)7.57Chemaxon
pKa (Strongest Basic)8.36Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count10Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area130.01 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity154.68 m3·mol-1Chemaxon
Polarizability61.99 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 29, 2022 17:34 / Updated at July 18, 2023 22:58